Statin use during pregnancy: A systematic review and meta-analysis

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 3, 2012, Pages 363-378

  Kusters, D Meeike ^a   Lahsinoui, Hajar Hassani ^a   Van De Post, Joris A M ^a   Wiegman, Albert ^a   Wijburg, Frits A ^a   Kastelein, John J P ^a   Hutten, Barbara A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

congenital anomalies; hypercholesterolemia; pregnancy; statins; teratogenic effects

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABORTION; APLASIA; ARM MALFORMATION; CLEFT LIP; CONGENITAL MALFORMATION; DOSE RESPONSE; DRUG SAFETY; FEMALE; FETAL WELL BEING; GRANULATION TISSUE; HAND MALFORMATION; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOSPADIAS; INTRAUTERINE GROWTH RETARDATION; LIVE BIRTH; MACROSOMIA; META ANALYSIS; METABOLIC DISORDER; NONHUMAN; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURITY; PRENATAL DRUG EXPOSURE; RESPIRATORY DISTRESS; REVIEW; SIDE EFFECT; SMALL FOR DATE INFANT; SOFT TISSUE DISEASE; SPONTANEOUS ABORTION; STILLBIRTH; SYNDROME VATER; SYSTEMATIC REVIEW; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 84858245267     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.196     Document Type: Review

References (66)

1. Thorogood M, Seed M, De Mott K. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG 116(4), 478-479 (2009).
2. Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 337, a2423 (2008).
3. Andrade SE, Raebel MA, Brown J et al. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol. Drug Saf. 17(3), 240-247 (2008). (Pubitemid 351404035)
4. Kulaga S, Zargarzadeh AH, Berard A. Prescriptions filled during pregnancy for drugs with the potential of fetal harm. BJOG 116(13), 1788-1795 (2009).
5. Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur. J. Clin. Pharmacol. 64(11), 1125-1132 (2008).
6. Cooper WO, Hickson GB, Ray WA. Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr. Perinat. Epidemiol. 18(2), 106-111 (2004). (Pubitemid 38374263)
7. Napoli C, D'Armiento FP, Mancini FP et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Invest. 100(11), 2680-2690 (1997). (Pubitemid 28007535)
8. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 354(9186), 1234-1241 (1999). (Pubitemid 29469351)
9. Alkemade FE, Gittenberger-de Groot AC, Schiel AE et al. Intrauterine exposure to maternal atherosclerotic risk factors increases the susceptibility to atherosclerosis in adult life. Arterioscler. Thromb. Vasc. Biol. 27(10), 2228-2235 (2007). (Pubitemid 350287254)
10. Ness RB, Harris T, Cobb J et al. Number of pregnancies and the subsequent risk of cardiovascular disease. N. Engl. J. Med. 328(21), 1528-1533 (1993). (Pubitemid 23147782)
11. Van der Graaf A, Vissers MN, Gaudet D et al. Dyslipidemia of mothers with familial hypercholesterolemia deteriorates lipids in adult offspring. Arterioscler. Thromb. Vasc. Biol. 30(12), 2673-2677 (2010).
12. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Cochrane Handbook for Sytematic Reviews of Intervention (Version 5.0.1 Edition). Higgins JPT, Green S (Eds). The Cochrane Collaboration, London, UK (2008).
13. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses (2011).
14. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br. J. Clin. Pharmacol. 64(4), 496-509 (2007). (Pubitemid 47404298)
15. Taguchi N, Rubin ET, Hosokawa A et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod. Toxicol. 26(2), 175-177 (2008).
16. McGrogan A, Snowball J, De Vries CS. Statins and pregnancy outcomes: a cohort study in the GPRD. Pharmacoepidemiology 18(Suppl. 1), S75-S76 (2009).
17. Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res. A Clin. Mol. Teratol. 73(11), 888-896 (2005). (Pubitemid 41742199)
18. Freyssinges C, Ducrocq MB. Simvastatin and pregnancy. Therapie 51(5), 537-542 (1996).
19. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am. J. Med. Genet. A 131(3), 287-298 (2004).
20. Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA. Maternal exposure to statins and risk for birth defects: a case-series approach. Am. J. Med. Genet. A 146A(20), 2701-2705 (2008).
21. Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod. Toxicol. 18(4), 619-621 (2004). (Pubitemid 38609293)
22. Teelucksingh S, El-Youssef J, Sohan K, Ramsewak S. Prolonged inadvertent pravastatin use in pregnancy. Reprod. Toxicol. 18(2), 299-300 (2004). (Pubitemid 38333053)
23. Vagt A, Kastendieck C. Probable congenital anomaly after exposure to atorvastatin in early pregnancy. From the Bremen register of drug-related diseases. Tagliche Praxis 41, 409-412 (2000). (Pubitemid 30604696)
24. Seguin J, Samuels P. Fluvastatin exposure during pregnancy. Obstet. Gynecol. 93(5 Pt 2), 847 (1999). (Pubitemid 29197922)
25. Ghidini A, Sicherer S, Willner J. Congenital abnormalities (VATER) in baby born to mother using lovastatin. Lancet 339(8806), 1416-1417 (1992).
26. Trakadis Y, Blaser S, Hahn CD, Yoon G. A case report of prenatal exposure to rosuvastatin and telmisartan. Paediatr. Child Health 14(7), 450-452 (2009).
27. Wise LD, Prahalada S, Robertson RT, Bokelman DL, Akutsu S, Fujii T. Simvastatin (MK-0733): oral teratogenicity study in rabbits. Yakuri to Chiryo 39(2), 159-167 (1990). (Pubitemid 20198445)
28. Tanase H, Asai M, Hirose K. Reproduction study of pravastatin sodium administered during the period of fetal organogenesis in rabbits. Jap. Pharmacol. Ther. 15(12), 67-73 (1987). (Pubitemid 18037731)
29. Dostal LA, Schardein JL, Anderson JA. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. Teratology 50(6), 387-394 (1994).
30. Lankas GR, Cukierski MA, Wise LD. The role of maternal toxicity in lovastatin-induced developmental toxicity. Birth Defects Res. B Dev. Reprod. Toxicol. 71(3), 111-123 (2004). (Pubitemid 39031151)
31. Henck JW, Craft WR, Black A, Colgin J, Anderson JA. Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. Toxicol. Sci. 41(1), 88-99 (1998). (Pubitemid 28201532)
32. Hrab RV, Hartman HA, Cox RH. Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation. Teratology 50(1), 19-26 (1994). (Pubitemid 24246848)
33. Tanase H, Hirose K. Reproduction study of pravastatin sodium administered during the period of fetal organogenesis in rats. Jap. Pharmacol. Ther. 15(12), 45-56 (1987). (Pubitemid 18037729)
34. Tanase H, Hirose K. Reproduction study of pravastatin sodium administered prior to and in the early stages of pregnancy in rats. Jap. Pharmacol. Ther. 15(12), 37-44 (1987). (Pubitemid 18037728)
35. Minsker DH, MacDonald JS, Robertson RT, Bokelman DL. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Teratology 28(3), 449-456 (1983). (Pubitemid 14220121)
36. Wise LD, Majka JA, Robertson RT et al. Simvastatin (MK-0733): oral teratogenicity study in rats. Pre- and postnatal observation. Yakuri to Chiryo 39(2), 143-158 (1990).
37. Elahi MM, Cagampang FR, Anthony FW, Curzen N, Ohri SK, Hanson MA. Statin treatment in hypercholesterolemic pregnant mice reduces cardiovascular risk factors in their offspring. Hypertension 51(4), 939-944 (2008). (Pubitemid 351654708)
38. Honein MA, Paulozzi LJ, Cragan JD, Correa A. Evaluation of selected characteristics of pregnancy drug registries. Teratology 60(6), 356-364 (1999).
39. Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv. Exp. Med. Biol. 686, 349-364 (2010).
40. Scialli AR. 2005 Josef Warkany lecture: clinicians. Birth Defects Res. A Clin. Mol. Teratol. 76(1), 1-6 (2006). (Pubitemid 43227672)
41. Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J. Obstet. Gynaecol. Can. 29(11), 906-908 (2007).
42. Frias JL, Gilbert-Barness E. Human teratogens: current controversies. Adv. Pediatr. 55, 171-211 (2008).
43. Avis HJ, Hutten BA, Twickler MT et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? Curr. Opin. Lipidol. 20(6), 484-490 (2009).
44. Gibb H, Scialli AR. Statin drugs and congenital anomalies. Am. J. Med. Genet. A 135(2), 230-231 (2005).
45. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod. Toxicol. 10(6), 439-446 (1996). (Pubitemid 27030088)
46. Macintosh MC, Fleming KM, Bailey JA et al. Perinatal mortality and congenital anomalies in babies of women with Type 1 or Type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ 333(7560), 177 (2006).
47. Satpathy HK, Fleming A, Frey D, Barsoom M, Satpathy C, Khandalavala J. Maternal obesity and pregnancy. Postgrad. Med. 120(3), E01-E09 (2008).
48. Brent RL, Beckman DA. The contribution of environmental teratogens to embryonic and fetal loss. Clin. Obstet. Gynecol. 37(3), 646-670 (1994). (Pubitemid 24323543)
49. Edison RJ, Berg K, Remaley A et al. Adverse birth outcome among mothers with low serum cholesterol. Pediatrics 120(4), 723-733 (2007). (Pubitemid 47549559)
50. Bertrand N, Dahmane N. Sonic hedgehog signaling in forebrain development and its interactions with pathways that modify its effects. Trends Cell Biol. 16(11), 597-605 (2006). (Pubitemid 44636221)
51. Napoli C, de Nigris F, Welch JS et al. Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. Circulation 105(11), 1360-1367 (2002). (Pubitemid 34260429)
52. Palinski W, D'Armiento FP, Witztum JL et al. Maternal hypercholesterolemia and treatment during pregnancy influence the long-term progression of atherosclerosis in offspring of rabbits. Circ. Res. 89(11), 991-996 (2001). (Pubitemid 34640865)
53. Palinski W, Napoli C. The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J. 16(11), 1348-1360 (2002). (Pubitemid 34913307)
54. Napoli C, Witztum JL, Calara F, de Nigris F, Palinski W. Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses. Circ. Res. 87(10), 946-952 (2000).
55. Kenis I, Tartakover-Matalon S, Cherepnin N et al. Simvastatin has deleterious effects on human first trimester placental explants. Hum. Reprod. 20(10), 2866-2872 (2005). (Pubitemid 41487645)
56. Henshaw SK. Unintended pregnancy in the United States. Fam. Plann. Perspect. 30(1), 242-249 (1998).
57. Martin U, Davies C, Hayavi S, Hartland A, Dunne F. Is normal pregnancy atherogenic? Clin. Sci. (Lond.) 96(4), 421-425 (1999).
58. Berge LN, Arnesen E, Forsdahl A. Pregnancy related changes in some cardiovascular risk factors. Acta Obstet. Gynecol. Scand. 75(5), 439-442 (1996). (Pubitemid 26225881)
59. Amundsen AL, Khoury J, Iversen PO et al. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis 189(2), 451-457 (2006). (Pubitemid 44740297)
60. Roes EM, Sieben R, Raijmakers MT, Peters WH, Steegers EA. Severe preeclampsia is associated with a positive family history of hypertension and hypercholesterolemia. Hypertens. Pregnancy 24(3), 259-271 (2005). (Pubitemid 41579636)
61. Redecha P, Van RN, Torry D, Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 113(17), 4101-4109 (2009).
62. Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G. A new mouse model to explore therapies for preeclampsia. PLoS One 5(10), e13663 (2010).
63. Castro LC, Avina RL. Maternal obesity and pregnancy outcomes. Curr. Opin. Obstet. Gynecol. 14(6), 601-606 (2002). (Pubitemid 36015878)
64. Sedgh G, Henshaw S, Singh S, Ahman E, Shah IH. Induced abortion: estimated rates and trends worldwide. Lancet 370(9595), 1338-1345 (2007). (Pubitemid 47539568)
65. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 315(7099), 32-34 (1997). (Pubitemid 27271683)
66. World Health Organization. National, regional, and worldwide estimates of stillbirth rates in 2009 with trends since 1995. WHO, Geneva, Switzerland (2011).